Letters Academic sponsorship

Time to treat as independent

BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c6837 (Published 30 November 2010) Cite this as: BMJ 2010;341:c6837
  1. Tom MacDonald, professor of clinical pharmacology1,
  2. Chris Hawkey, professor of gastroenterology2,
  3. Ian Ford, professor of biostatistics3
  1. 1Medicines Monitoring Unit, Division of Medical Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
  2. 2University Hospital Nottingham, Wolfson Digestive Diseases Centre, Nottingham NG7 2UH, UK
  3. 3Robertson Centre for Biostatistics, University of Glasgow, Glasgow G12 8QQ, UK
  1. tom{at}memo.dundee.ac.uk

In response to the rosiglitazone affair, Steinbrook and Kassirer suggest that more trials should be sponsored, funded, and conducted by organisations independent of industry.1 We agree. We operate close to that model with two studies requested by the European Medicines Agency. Academics wrote the protocols, collaborators are academic, and the study data …

Sign in

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe